Since its FDA approval in 2002, Atomoxetine (brand name Strattera) has become a second or third line option (after stimulants and sometimes after central alpha agonists) for ADHD in both children and adults. Does it work? Listen and find out!
We hope this trio of 60-second psych podcasts is a start at addressing the impact of systemic inequity:
Promoting Assertiveness in Adolescents
Preventing Trauma With Racial Socialization
You Might Also Enjoy...
Since its FDA approval in 2002, Atomoxetine (brand name Strattera) has become a second or third line option (after stimulants and sometimes after central alpha agonists) for ADHD in both children and adults. Does it work? Listen and find out!
ADHD is one of the most treatable conditions in psychiatry if patients adhere to medication regimens. So, why are parents so resistant to stimulant medications and how can we approach these misconceptions?
Each year in the US, there are about 1.04 million divorces, affecting about 800,000 children. How can we navigate the complexities of treating a child with divorce?
Do antipsychotics have neurotoxic effects in youth? In this episode, we’ll be banging the drum of caution about antipsychotic use in children and adolescents.
With a growing body of evidence supporting its clinical efficacy and cost-effectiveness relative to traditional ABA approaches, the developmental model is being used with increasing prevalence across the US.
Prescribing Psychotropics bridges the gap between the complexities of drug pharmacokinetics and everyday clinical practice, providing clinicians more insight into how psychiatric drugs behave (or misbehave!) once their patients take them.